Evidence map›Paper›PMID 42497864›Full record

ArticleCell reports. Medicine2026

CRISPR-Cas9-producing probiotic bacteria for editing NOX2/gp91

Chen Zhang, Tianyu Li, Huoye Hao, Gang Wang, Yuzhe Zhang, Yue Huang, Lili Chen, Jin Wang, Xiang-Jiao Yang, Xiuli Bi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chen ZhangCollege of Life Science, Liaoning University, Shenyang 110036, China.
Tianyu LiCollege of Life Science, Liaoning University, Shenyang 110036, China.
Huoye HaoCollege of Life Science, Liaoning University, Shenyang 110036, China.
Gang WangCollege of Life Science, Liaoning University, Shenyang 110036, China.
Yuzhe ZhangCollege of Life Science, Liaoning University, Shenyang 110036, China.
Yue HuangCollege of Life Science, Liaoning University, Shenyang 110036, China.
Lili ChenCollege of Life Science, Liaoning University, Shenyang 110036, China.
Jin WangCollege of Life Science, Liaoning University, Shenyang 110036, China.
Xiang-Jiao YangRosalind and Morris Goodman Cancer Institute & Department of Medicine, McGill University, Montreal, QC H3A 1A3, Canada.
Xiuli BiCollege of Life Science, Liaoning University, Shenyang 110036, China; Key Laboratory for Chronic Diseases Molecular Mechanism Research and Nutritional Intervention of Shenyang, Shenyang 110036, China. Electronic address: xiulibi@lnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary pathogenic mechanism of inflammatory bowel disease (IBD) involves elevated levels of reactive oxide species (ROS) in the gut, leading to oxidative stress and damage to the intestinal barrier function. We engineered a non-pathogenic bacterial strain, Escherichia coli Nissle 1917 (EcN), for oral CRISPR-Cas9 delivery to edit NOX2 (encoding the gp91

Indexed as

CRISPR-Cas SystemsEscherichia coliGene EditingInflammatory Bowel DiseasesNADPH Oxidase 2ProbioticsAnimalsColitisDextran SulfateDisease Models, AnimalHumansIntestinal Barrier FunctionMiceMice, Inbred C57BLOxidative StressRAW 264.7 CellsCybb protein, mouseDextran SulfateNADPH Oxidase 2Reactive Oxygen SpeciesCRISPR-Cas9genome editinghydrogelinflammatory bowel diseaseNOX2probiotic bacteriareactive oxygen species

Identifiers

PMID42497864
PMCPMC13522793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.